These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 25755422)

  • 21. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD).
    Duseja A; Chalasani N
    Hepatol Int; 2013 Dec; 7 Suppl 2():755-64. PubMed ID: 26202291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology and natural history of patients with NAFLD.
    Bhala N; Younes R; Bugianesi E
    Curr Pharm Des; 2013; 19(29):5169-76. PubMed ID: 23394091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are statins 'IDEAL' for non-alcoholic fatty liver disease?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Curr Med Res Opin; 2014 Feb; 30(2):229-31. PubMed ID: 24127654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic fatty liver disease: A growing public health problem in Turkey.
    Kaya E; Yılmaz Y
    Turk J Gastroenterol; 2019 Oct; 30(10):865-871. PubMed ID: 31258135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".
    Manti S; Romano C; Chirico V; Filippelli M; Cuppari C; Loddo I; Salpietro C; Arrigo T
    Hepat Mon; 2014 May; 14(5):e17641. PubMed ID: 24829591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma.
    Said A; Ghufran A
    World J Clin Oncol; 2017 Dec; 8(6):429-436. PubMed ID: 29291167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention.
    Motta BM; Masarone M; Torre P; Persico M
    Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Murine models provide insight to the development of non-alcoholic fatty liver disease.
    Reid DT; Eksteen B
    Nutr Res Rev; 2015 Dec; 28(2):133-142. PubMed ID: 26494024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review.
    Tariq R; Axley P; Singal AK
    J Clin Exp Hepatol; 2020; 10(1):81-87. PubMed ID: 32025167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations.
    Kumar R; Priyadarshi RN; Anand U
    J Clin Transl Hepatol; 2020 Mar; 8(1):76-86. PubMed ID: 32274348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of Non-alcoholic Fatty Liver Disease in India: A Systematic Review and Meta-analysis.
    Shalimar ; Elhence A; Bansal B; Gupta H; Anand A; Singh TP; Goel A
    J Clin Exp Hepatol; 2022; 12(3):818-829. PubMed ID: 35677499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obstructive sleep apnea and non-alcoholic Fatty liver disease: is the liver another target?
    Mirrakhimov AE; Polotsky VY
    Front Neurol; 2012; 3():149. PubMed ID: 23087670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ASH and NASH.
    Scaglioni F; Ciccia S; Marino M; Bedogni G; Bellentani S
    Dig Dis; 2011; 29(2):202-10. PubMed ID: 21734385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.
    Serfaty L; Lemoine M
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):634-7. PubMed ID: 19195623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.